Less Ads, More Data, More Tools Register for FREE

Pin to quick picksProvexis Regulatory News (PXS)

Share Price Information for Provexis (PXS)

Share Price is delayed by 15 minutes
Get Live Data
1.01    0.07 (7.45%)
Bid:
0.94
Ask:
1.08
Spread: 0.14 (14.894%)
Market Cap: £22.05m
PXS Live PriceLast checked at - London Stock Exchange

Intraday Provexis Share Chart

Fruitflow powder has GRAS status affirmed in US

30 Apr 2013 07:00

RNS Number : 5282D
Provexis PLC
30 April 2013
 



30 April 2013

Provexis plc

 

Fruitflow® powder has GRAS status affirmed in the United States

 

Provexis plc ("Provexis" or the "Company"), a business that develops, licenses and markets scientifically-proven functional food and sports nutrition technologies, announces that an independent Expert Panel in the United States has affirmed the powder version of the company's Fruitflow® heart-health ingredient to be Generally Recognised as Safe ('GRAS'), paving the way for the powder version of Fruitflow® to be marketed in the United States.

 

The powder version of Fruitflow® has been scaled up and commercialised by the company's Alliance partner DSM Nutritional Products ("DSM") and first orders have been received from six customers in international markets. The powder version is suitable for a range of dietary supplement products including soft gels, capsules and tablets, and it will enable manufacturers to target a broader consumer base. DSM has launched the powder version of Fruitflow® internally to its global sales force, and the product will be launched commercially by DSM at the Vitafoods exhibition in Geneva on 14 May.

 

Stephen Moon, CEO of Provexis, commented:

"GRAS affirmation of the powder version of Fruitflow is a significant development for the product which will help to unlock the substantial commercial opportunities available in North America. Our Alliance with DSM has made very good progress in commencing the commercialisation of Fruitflow, and GRAS affirmation of Fruitflow powder will help to drive the continuing good levels of customer interest from a range of customers across the globe."

 

ends-

 

For further information please contact:

 

Provexis plc

Stephen Moon, Chief Executive Tel: 01753 861777

 

Cenkos Securities plc

Max Hartley / Bobbie Hilliam Tel: 020 7397 8900

 

Haggie Financial LLP

Matthew Longbottom / Peter Rigby Tel: 020 7417 8989

matthew.longbottom@haggie.co.uk

 

 

Notes to Editors

 

About Fruitflow®

Fruitflow®, a water-soluble tomato concentrate developed by Provexis, is a breakthrough in anti-thrombotic food technology. In human trials, consumption of Fruitflow® has been proven to reduce platelet aggregation in 97% of subjects. The effect takes place within three hours of consumption and lasts for up to eighteen hours, making it ideal for daily dosage in functional foods or dietary supplements. The syrup version of Fruitflow® can be used as an ingredient in food and beverages, and the powder version is suitable for a range of dietary supplement products including soft gels, capsules and tablets.

 

The syrup and powder versions of Fruitflow® are GRAS (Generally Regarded as Safe) in the US and are not regarded as Novel Foods in the EU, clearing them for wide use in foods, beverages and supplements. In May 2009, the Fruitflow® technology was the first to be substantiated by the European Food Safety Authority ("EFSA") under the new Article 13(5) for proprietary and emerging science. In December 2009 the European Commission authorised the health claim "Helps maintain normal platelet aggregation, which contributes to healthy blood flow", which was the first wording to be authorised under Article 13(5).

 

The technology has been granted patents in the EU, US, Australia, Canada and Mexico, with Japan pending. Further patents have been filed for the bioactive components of Fruitflow® and for other developmental areas such as deep vein thrombosis and triglyceride lowering.

 

About Royal DSM N.V.

Royal DSM is a global science-based company active in health, nutrition and materials. By connecting its unique competences in Life Sciences and Materials Sciences DSM is driving economic prosperity, environmental progress and social advances to create sustainable value for all stakeholders. DSM delivers innovative solutions that nourish, protect and improve performance in global markets such as food and dietary supplements, personal care, feed, pharmaceuticals, medical devices, automotive, paints, electrical and electronics, life protection, alternative energy and bio-based materials. DSM's 23,500 employees deliver annual net sales of about €9.1 billion. The company is listed on NYSE Euronext. More information can be found at www.dsm.com.

 

About DSM Nutritional Products

DSM Nutritional Products, a wholly-owned business unit of Royal DSM N.V., is one of the world's leading suppliers of vitamins, carotenoids and other ingredients to the feed, food, pharmaceutical and personal care industries. The business has sales of more than €3 billion and a long tradition of innovation that benefits people, planet and profit. DSM Nutritional Products is a fully integrated global operation, organised into three market-facing businesses: Animal nutrition & health, Human nutrition & health and Personal care.

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
MSCEAKLNASFDEFF
Date   Source Headline
20th May 20267:00 amRNSHolding(s) in Company
16th Apr 202612:37 pmRNSHolding(s) in Company
31st Dec 20258:22 amRNSHalf-year Financial Report
31st Dec 20258:22 amRNSHalf-year Financial Report
21st Nov 20251:38 pmRNSResult of AGM
30th Oct 20257:30 amRNSRestoration - Provexis plc
30th Oct 20257:00 amRNSFinal Results
1st Oct 20257:30 amRNSSuspension - Provexis PLC
30th Sep 20258:40 amRNSDelay in publication of annual accounts
7th Jan 20251:14 pmRNSGrant of Options and Warrants
31st Dec 20241:00 pmRNSTotal Voting Rights
31st Dec 20249:59 amRNSHalf-year Report
18th Dec 20247:00 amRNSPurchase of Fruitflow® II SD & royalty payment
25th Oct 20243:47 pmRNSResult of AGM
30th Sep 20247:00 amRNSFinal Results
30th Apr 20245:00 pmRNSTotal Voting Rights
28th Mar 20247:00 amRNSIssue of Equity - purchase of Fruitflow® II SD
29th Dec 202312:48 pmRNSHalf-year Report
26th Oct 20231:51 pmRNSResult of AGM
29th Sep 20237:00 amRNSFinal Results
30th Aug 20237:04 amRNSBYHEALTH regulatory filing with Chinese SAMR
3rd Apr 20237:00 amRNSCapital structure and funding update
24th Jan 202311:03 amRNSGrant of Share Options
30th Dec 20228:53 amRNSHalf-year Report
27th Oct 20221:12 pmRNSResult of AGM
14th Oct 20227:00 amRNSDirectorate Change
30th Sep 20227:00 amRNSFinal Results
22nd Jun 20227:00 amRNSTwo new agreements with DSM & patent application
31st May 20225:00 pmRNSTotal Voting Rights
17th May 202212:39 pmRNSExercise of Options and Total Voting Rights
31st Dec 20217:00 amRNSHalf-year Report
26th Nov 20214:41 pmRNSSecond Price Monitoring Extn
26th Nov 20214:36 pmRNSPrice Monitoring Extension
4th Nov 20211:30 pmRNSResult of AGM
4th Nov 202111:07 amRNSBy-Health Fruitflow agreement and support in R&D
1st Oct 20216:04 pmRNSGrant of Share Options
30th Sep 20217:00 amRNSFinal Results
9th Sep 20214:41 pmRNSSecond Price Monitoring Extn
9th Sep 20214:35 pmRNSPrice Monitoring Extension
24th Aug 20214:35 pmRNSPrice Monitoring Extension
22nd Jul 20214:40 pmRNSSecond Price Monitoring Extn
22nd Jul 20214:35 pmRNSPrice Monitoring Extension
21st Jul 20214:41 pmRNSSecond Price Monitoring Extn
21st Jul 20214:36 pmRNSPrice Monitoring Extension
5th Jul 20214:35 pmRNSPrice Monitoring Extension
1st Jul 20214:40 pmRNSSecond Price Monitoring Extn
1st Jul 20214:35 pmRNSPrice Monitoring Extension
26th Feb 20215:00 pmRNSTotal Voting Rights
19th Feb 20217:30 amRNSDirector / PDMR notification
19th Feb 20217:00 amRNSPlacing of new ordinary shares to raise £50,000

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.